
The Promise of AI and Cardiovascular Diseases for PCPs
In an official statement, the American Heart Association (AHA) said it supports the creation of tools and services that would 'further the science and practice of precision medicine by enabling more precise approaches to cardiovascular and stroke research, prevention and care of individuals and populations.'
Nevertheless, the AHA continued, 'several challenges exist, and few artificial intelligence tools have been shown to improve cardiovascular and stroke care sufficiently to be widely adopted.'
Still, AI isn't going anywhere, and the push for its use in cardiovascular disease prediction and treatment will only increase.
'AI is everywhere in the healthcare system,' said Hector Garcia-Garcia, MD, an interventional cardiologist with MedStar, based in Washington, D.C. 'AI tools are involved with labs, imaging, values, and more, and it's well integrated into electronic medical records today.'
Hector Garcia-Garcia, MD
The role of primary care physicians (PCPs) continues to be critical in heart disease detection. As frontline healthcare workers, PCPs are generally the first to note something amiss when it comes to patient cardiovascular health.
'PCPs are crucial to identifying cardiovascular health risks,' said Anthony Mercando, MD, a cardiologist at White Plains Hospital Physician Associates in New York City. 'They take family histories, do physical exams, and get blood panel results, all of which may show cause for investigating heart health.'
While all these traditional tools have long led PCPs to refer patients to their cardiologist peers, today AI is increasingly involved in screening. And that may be a boon, as a high percentage of heart diseases go undiagnosed.
The AI-Enhanced Tools
If there's a traditional workhorse in the world of heart disease, it's the stethoscope. And now, AI has joined the show, promising to enhance the tool's ability to pick up subtle changes. Preliminary studies have demonstrated that AI-enhanced stethoscopes may lead to higher discovery and earlier diagnosis of cardiac murmurs associated with valvular heart disease, which affects 1 in 10 adults older than 65 years.
The new stethoscopes work by making a 30- to 60-second recording of the patient's heart and lung sounds. Doctors also hear the sounds with greater clarity, thanks to amplification and noise cancellation. From here, AI steps in, instantly analyzing the sounds and ECG data to deliver a full picture of cardiac health — sometimes in as quickly as 15 seconds. The stethoscope represents a big step forward in early diagnosis, according to a Lancet-published study.
Mercando is a fan of the new tool.
'We're doing a pilot here to screen patients who are not yet symptomatic or have abnormal test results,' he said. 'It's an exciting tool to pick up disease earlier in the process, and it's a tool that any healthcare practitioner can use.'
The stethoscope is one example of how AI can enhance diagnosis of heart diseases, and represents a low-cost, frontline tool that PCPs can add to their practices. Other tools are less obvious, at least to the patient.
One of these is imaging, a key player in heart disease diagnosis. CT scans of the heart have long been stalwarts in recognizing heart disease. For a relatively low cost, a scan can reveal three-dimensional images of a heart and its surrounding structures. Cardiac CT may involve contrast dye to reveal the moving heart and blood vessels.
In the AI-enhanced version, CT can produce faster analysis of the images it takes. 'The AI is digging into hundreds of data points and is key in making the results faster,' said Garcia-Garcia. 'The results are always supervised by a cardiologist, but the AI is giving us the ability to identify red flags faster and earlier.'
Anthony Mercando, MD
Still, as with other uses of AI in medicine, it's important to recognize the clinical correctness of the results may not be perfect— thus the continued need for human intervention. According to the AHA's statement on CT imaging using AI, the applications are now 'capable of automating the computing of coronary artery calcium score' from low-dose CT or even from nuclear imaging studies.
'There's no AI tool in the United States that isn't supervised by the doctor, so the final word lies with the doctor,' said Garcia-Garcia. 'Therefore, there is no real downside.'
At Mercando's community hospital, the newly created position of AI coordinator is looking into relevant applications for AI. One of those is a solution that looks at every chest CT and creates a calcium score. 'When you have a tool that can predict risk and allow specialists to treat patients earlier, you are saving lives,' said Mercando.
Going Forward
As a PCP, you may or may not be tuned into how AI is helping your cardiac/potential cardiac patients. But as the technology becomes more widespread and the public becomes more aware, patients may bring it into conversation.
'A classic example is how AI is now reading mammograms, identifying differences from 1 year to the next,' said Mercando. 'Patients are aware of this and now asking for it. The same may carry over to heart disease — patients are supportive of the technology.'
AI in cardiac care isn't limited to stethoscopes and CT — its tentacles are beginning to reach into structural interventions like measuring stenosis, and by automatically detecting intracranial hemorrhage in stroke diagnosis.
In its statement, the AHA warns against AI limitations specific to imaging. The group points to sourcing, curating, and sharing appropriate data as one sticking point, along with questions surrounding the appropriate reporting of results using accepted statistical measures. The AHA suggests that deep learning algorithms may be enhanced by using a new medical imaging data readiness scale for improved outcomes.
As with all medical uses of AI, the AHA also cautions against bias leading to health inequities. The organization encourages the development of AI learning models that involve underrepresented races in cardiac care. The tool is far from perfected yet, but its potential will continue to intrigue doctors of all stripes, including cardiologists.
Moving forward, the fact that AI will play an increasingly larger role in cardiovascular screening isn't up for debate. What is debatable is the point when will the tool be useful to improving patient outcomes at scale. In the AHA's opinion, the answer lies in the need to mitigate bias and ensure education and access to AI technologies. Only then, said the organization, can AI realize its full potential.
From his perspective, Garcia-Garcia views AI's role in cardiovascular care as a game changer. 'AI can change how a patient is treated,' he said. 'Early detection gets patients to specialists sooner, and that saves lives.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Recombinant Human Hair Keratin Protein Market 2025 Trends and Updates
The global recombinant human hair keratin protein market is growing quickly as more people seek effective hair health solutions and advanced wound healing treatments, says a study published by Towards Healthcare a sister firm of Precedence Research. Ottawa, Aug. 14, 2025 (GLOBE NEWSWIRE) -- The global recombinant human hair keratin protein market is on a strong growth trajectory, with revenues expected to climb into the hundreds of millions by 2034. This momentum is being fueled by a rising focus on hair health, a noticeable increase in bleeding disorder cases, and a wave of fresh investments pouring into biotechnology. Together, these factors are creating fertile ground for innovation and demand across multiple industries. Companies in North America, Asia-Pacific, and Europe are actively investing in research, driving innovations, and forming partnerships to open new market opportunities. The Complete Study is Now Available for Immediate Access | Download the Sample Pages of this Report @ Key Takeaways North America dominated the recombinant human hair keratin protein market in 2024. Asia Pacific is estimated to grow at the fastest CAGR during the forecast period. Market Overview & Potential Recombinant human hair keratin protein is a lab-engineered protein that replicates the structure and function of natural keratin in human hair. It is produced via recombinant DNA technology, resulting in a highly controlled and pure form of keratin that differs from traditional extracts. This makes it a valuable material for applications such as wound healing and hair care. Conventional keratin extraction methods can be inconsistent and may not yield pure products, whereas recombinant production ensures greater purity and enables precise control over the protein's amino acid sequence and structure, resulting in more predictable properties. Top Countries in Recombinant Human Hair Keratin Protein Market: United States Contribution: Leading the global market with strong demand for medical-grade recombinant keratin, supported by a robust biotech ecosystem and healthcare infrastructure. Strength: Advanced R&D capabilities and regulatory support for therapeutic and regenerative applications. China Contribution: Fastest-growing market, fueled by a rapidly expanding cosmetics and personal care sector. Strength: Strong domestic production capabilities, rising consumer awareness, and increasing investment in biotech innovations. Germany Contribution: Key contributor in Europe, especially in high-purity recombinant keratin for medical and cosmetic formulations. Strength: Expertise in biotechnology and demand for premium, high-performance personal care products. France Contribution: Strong market for cosmetic applications, particularly in haircare and skincare products incorporating natural bioactive ingredients. Strength: Sophisticated beauty industry and preference for sustainable, biologically derived ingredients. India Contribution: Emerging player in both medical and cosmetic applications of recombinant keratin. Strength: Large population base, rising demand for advanced hair and skin treatments, and growing domestic manufacturing activity. You can place an order or ask any questions, please feel free to contact us at sales@ What is the Growth Potential Responsible for The Growth of The Recombinant Human Hair Keratin Protein Market? The growth of the market is driven by the growing application in the biomedical field due to its biocompatibility, ability to promote cell growth, and biodegradability, which makes it ideal for various medical uses, driving the growth. The key applications, like tissue regeneration, drug delivery systems, and wound healing, are supporting the growth of the market. Other key drivers are biotechnology research due to the growing biotechnology sector, in personal care and cosmetics, and sustainable and ethical sourcing. Increasing incidence of chronic diseases, and government initiatives in R&D in life sciences research and development. What Are the Growing Trends Associated with the Recombinant Human Hair Keratin Protein Market? The technological advancements like innovation in synthetic biology and demonstration technology for the development of new and tailored properties, and more efficient production methods. Rising demand in the cosmetic sector for the development of hair care products for improving the shine, strengthening the damaged hair, and reducing the frizz increases the demand for the product. The growing biomedical applications, like in wound healing, tissue engineering, and drug delivery, fuel the demand for the product, supporting the growth. Shift towards sustainable and ethical products, like growing demand and interest in vegan and plant-based keratins, improves the market growth of the market. Increasing awareness and adoption due to the benefits offered and availability of the products make it a preferred choice, and increase the growth. What Is the Growing Challenge in the Recombinant Human Hair Keratin Protein Market? However, the recombinant human hair keratin protein market faces challenges including production issues, consistency concerns, and consumer perceptions. Although recombinant technology provides advantages like higher purity and specific amino acid composition, it also risks problems like misfolding, aggregation, and low yields. Additionally, high production costs, especially due to specialized equipment and chemicals, can hinder market growth. Consumer preferences for natural or plant-based products, along with safety and efficacy concerns regarding keratin treatments, could also limit market expansion. Get the latest insights on life science industry segmentation with our Annual Membership: Regional Analysis How Did North America Dominate the Recombinant Human Hair Keratin Protein Market in 2024? North America led the recombinant human hair keratin protein market in 2023. Growth is driven by increased investments, collaborations, key industry players, and advanced R&D activities. The US and Canada are the primary markets, with companies like Novus Biologicals, Abcam Ltd., PROGEN, and OriGene contributing significantly. US government initiatives to promote biotech research further boost the market, complemented by over 130 recombinant proteins approved by the US FDA for clinical use. In the UK, industries are exploring innovative methods to enhance hair growth, quality, and reduce hair fall using recombinant human hair keratin protein. Additionally, rising awareness about hair health is fueling demand for these products. What Made Asia Pacific Significantly Grow in The Recombinant Human Hair Keratin Protein Market in 2024? Asia-Pacific is expected to grow the fastest in the recombinant human hair keratin protein market during the forecast period. Market growth is driven by increasing research and development activities, rising government funding, a growing number of bleeding disorder cases, favorable infrastructure, and lower costs. Recombinant keratin has been shown to promote skin wound healing and improve blood clotting. In China, about 65,000 people suffer from hemophilia, while India has the second-largest number of hemophilia cases worldwide, with 136,000 patients. The demand for products that support hair growth and reduce hair loss is rapidly increasing in China, South Korea, and Japan. Companies like Tsubaki use recombinant human keratin to develop luxurious hair treatments that attract beauty-conscious consumers. Become a valued research partner with us - Recent Developments In July 2024, Yuhan Corp, a South Korean pharmaceutical company, signed a comprehensive R&D collaboration agreement with ProGen. The collaboration was made to strengthen next-generation biologics and drug development research. In April 2024, Bio-Techne Corporation announced a strategic distribution agreement with Thermo Fisher Scientific. The agreement will distribute Bio-Techne's innovative products, such as antibodies, proteins, immunoassay kits, reagents, and enzymes, to laboratories and research institutions across Europe. Browse More Insights of Towards Healthcare: The global GMP grade cytokines market is valued at USD 2.54 billion in 2024, expected to rise to USD 2.79 billion in 2025, and anticipated to reach approximately USD 6.48 billion by 2034. This represents a steady growth trajectory at a CAGR of 9.84% from 2025 to 2034. The global recombinant proteins market is estimated at USD 3.36 billion in 2025 and is forecasted to climb to around USD 8.08 billion by 2034, expanding at a CAGR of 10.24% over the forecast period. The recombinant lysyl endopeptidase market was valued at USD 38 million in 2023 and is projected to reach USD 67.06 million by 2034, growing at a CAGR of 5.3% between 2024 and 2034. The global hair transplant market stands at USD 7.33 billion in 2024, rising to USD 8.87 billion in 2025, with projections indicating a surge to nearly USD 49.44 billion by 2034—signaling rapid expansion. The hair treatment drug market was worth USD 1.4 billion in 2023 and is anticipated to grow to USD 2.99 billion by 2034, recording a CAGR of 7.14% during 2024–2034. The global host cell protein testing market is valued at USD 2.37 billion in 2024, estimated to increase to USD 2.56 billion in 2025, and forecasted to hit USD 5.19 billion by 2034, with an expected CAGR of 8.17% from 2025 to 2034. The global protein expression technology market is pegged at USD 2.85 billion in 2024, projected to rise to USD 3.05 billion in 2025, and likely to reach USD 5.58 billion by 2034, reflecting a CAGR of 6.94% over the forecast timeline. The global proteinase K market is valued at USD 4.82 billion in 2024, forecasted to grow to USD 5.23 billion in 2025, and set to reach USD 10.93 billion by 2034, advancing at a CAGR of 8.54% between 2025 and 2034. The global cell-free protein expression market is valued at USD 315.03 million in 2024, expected to grow to USD 342.25 million in 2025, and projected to hit USD 716.26 million by 2034, expanding at a CAGR of 8.63% from 2025 to 2034. The global protein therapeutics market is calculated at USD 375.3 billion in 2024, projected to grow to USD 401.89 billion in 2025, and expected to reach USD 740.07 billion by 2034, advancing at a CAGR of 7.08% over the forecast period. Recombinant Human Hair Keratin Protein Market Key Players Abcam Limited Abbexa, Ltd. Bon Opus Biosciences Creative Diagnostics MyBioSource, Inc. Novus Biologicals OriGene PROGEN ProSpec Wuhan Huamei Biotech Co., Ltd. Regions Covered North America U.S. Canada Asia Pacific China Japan India South Korea Thailand Europe Germany UK France Italy Spain Sweden Denmark Norway Latin America Brazil Mexico Argentina Middle East and Africa (MEA) South Africa UAE Saudi Arabia Kuwait Access our exclusive, data-rich dashboard dedicated to the healthcare market - built specifically for decision-makers, strategists, and industry leaders. The dashboard features comprehensive statistical data, segment-wise market breakdowns, regional performance shares, detailed company profiles, annual updates, and much more. From market sizing to competitive intelligence, this powerful tool is one-stop solution to your gateway. Access the Dashboard: Immediate Delivery Available | Buy This Premium Research @ About Us Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics, with a strong emphasis on life science research. Dedicated to advancing innovation in the life sciences sector, we build strategic partnerships that generate actionable insights and transformative breakthroughs. As a global strategy consulting firm, we empower life science leaders to gain a competitive edge, drive research excellence, and accelerate sustainable growth. You can place an order or ask any questions, please feel free to contact us at sales@ Europe Region - +44 778 256 0738 North America Region - +1 8044 4193 44 Web: Find us on social platforms: LinkedIn | Twitter | InstagramError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21 minutes ago
- Yahoo
XRP stays flat as Bitcoin overtakes Google
XRP stays flat as Bitcoin overtakes Google originally appeared on TheStreet. Bitcoin's relentless climb pushed it to a fresh all-time high late Wednesday, briefly topping $124,450 and overtaking Google parent Alphabet's market capitalization before easing slightly. BTC overtook Google to become the fifth largest asset globally, hitting a $2.456 trillion market cap. The world's largest cryptocurrency now sits firmly above the $120,000 support level, cementing its position as the fifth-largest asset globally. The milestone, achieved during a late-night trading frenzy, was enough to trigger a wave of optimism among bulls. The move confirmed Bitcoin's strong institutional demand, with pension funds, ETFs, and large-cap investors driving unprecedented buying pressure. Ethereum followed suit, holding above $4,750, while Solana, Cardano, and Dogecoin all booked double-digit gains over the week. But one top-10 coin missed the rally entirely, XRP. Despite the sea of green across the crypto leaderboard, XRP stayed locked near $3.24 — virtually unchanged on the day — leaving traders scratching their heads. Data from Coinglass shows that more than $450 million worth of leveraged positions were liquidated in the past 24 hours, with the majority coming from short sellers who bet against Bitcoin's record-breaking run. With Bitcoin's valuation now over $2.4 trillion, traders are already eyeing the next prize, Apple's $3.462 trillion market cap. XRP stays flat as Bitcoin overtakes Google first appeared on TheStreet on Aug 14, 2025 This story was originally reported by TheStreet on Aug 14, 2025, where it first appeared. Inicia sesión para acceder a tu cartera de valores
Yahoo
21 minutes ago
- Yahoo
Intuitive Machines Stock Tumbles After Company Prices $300M Convertibles
Aug 14 - Shares of Intuitive Machines (NASDAQ:LUNR) fell about 10% in premarket trading on Thursday after the space-tech firm priced an upsized $300 million offering of 2.500% convertible senior notes due 2030. The deal jumped from an originally announced $250 million size and gives initial purchasers a 13-day window to buy an extra $45 million. The offering should close on Aug. 18, 2025. Warning! GuruFocus has detected 5 Warning Signs with LUNR. The notes carry a 2.500% annual coupon, payable semiannually each April 1 and Oct. 1 starting April 1, 2026. Intuitive Machines estimates net proceeds near $291.8 million after fees; roughly $32 million will cover capped-call hedges and the balance will fund general corporate purposes, including program advancement and runway support. Convertibles allow the companies to borrow at low rates now and leave optional deferred upside in the form of conversion to equity later, that structure has the effect of reducing immediate interest expense but causing possible share dilution in the future. This negative response by the market could have been prompted by an investor fear of dilution and timeframe as the company continues to achieve the next milestones. As the cash runway tightens on many small-space players, this capital raise could give Intuitive Machines some form of breathing room, with investors noting how the management intends to use it, whether important mission milestones play out, and how conversion mechanics could alter the number of shares in the period preceding 2030. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data